WASHINGTON, D.C.—Principal Investigator Gregg W. Stone, MD, explains the two-year outcomes of the SPIRIT IV trial, comparing the Xience V drug-eluting stent (Abbott) to the Taxus drug-eluting stent (Boston Scientific) for a primary endpoint of target lesion failure. He presented the results as a late-breaking clinical trial at the annual conference of Transcatheter Cardiovascular Therapeutics (TCT) Sept. 23. He comments that these results will continue to affect clinical practice, as “not all stents are created equal.”
Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."
Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.
